{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:14:15Z","timestamp":1773058455184,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Rationale<\/jats:title>\n                <jats:p>Unlike other antipsychotics, our previous positron emission tomography (PET) study demonstrated that a single dose of blonanserin occupied dopamine D<jats:sub>3<\/jats:sub> as well as dopamine D<jats:sub>2<\/jats:sub> receptors in healthy subjects. However, there has been no study concerning the continued use of blonanserin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>We examined D<jats:sub>2<\/jats:sub> and D<jats:sub>3<\/jats:sub> receptor occupancies in patients with schizophrenia who had been treated with blonanserin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirteen patients with schizophrenia participated. PET examinations were performed on patients treated with clinical dosage of blonanserin or olanzapine alone. A crossover design was used in which seven patients switched drugs after the first scan, and PET examinations were conducted again. D<jats:sub>2<\/jats:sub> and D<jats:sub>3<\/jats:sub> receptor occupancies were evaluated by [<jats:sup>11<\/jats:sup>C]-(+)-PHNO. We used nondisplaceable binding potential (BP<jats:sub>ND<\/jats:sub>) of 6 healthy subjects which we previously reported as baseline. To consider the effect of upregulation of D<jats:sub>3<\/jats:sub> receptor by continued use of antipsychotics, D<jats:sub>3<\/jats:sub> receptor occupancy by blonanserin in seven subjects who completed 2 PET scans were re-analyzed by using BP<jats:sub>ND<\/jats:sub> of olanzapine condition as baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Average occupancy by olanzapine (10.8 \u00b1 6.0 mg\/day) was as follows: caudate 32.8 \u00b1 18.3%, putamen 26.3 \u00b1 18.2%, globus pallidus \u2212 33.7 \u00b1 34.9%, substantia nigra \u2212 112.8 \u00b1 90.7%. Average occupancy by blonanserin (12.8 \u00b1 5.6 mg\/day) was as follows: caudate 61.0 \u00b1 8.3%, putamen 55.5 \u00b1 9.5%, globus pallidus 48.9 \u00b1 12.4%, substantia nigra 34.0 \u00b1 20.6%. EC<jats:sub>50<\/jats:sub> was 0.30 ng\/mL for D<jats:sub>2<\/jats:sub> receptor for caudate and putamen (df = 19, <jats:italic>p<\/jats:italic> &lt; 0.0001) and 0.70 ng\/mL for D<jats:sub>3<\/jats:sub> receptor for globus pallidus and substantia nigra (df = 19, <jats:italic>p<\/jats:italic> &lt; 0.0001). EC<jats:sub>50<\/jats:sub> for D<jats:sub>3<\/jats:sub> receptor of blonanserin changed to 0.22 ng\/mL (df = 13, <jats:italic>p<\/jats:italic> = 0.0041) when we used BP<jats:sub>ND<\/jats:sub> of olanzapine condition as baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study confirmed that blonanserin occupied both D<jats:sub>2<\/jats:sub> and D<jats:sub>3<\/jats:sub> receptors in patients with schizophrenia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00213-020-05698-3","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T16:10:35Z","timestamp":1605197435000},"page":"1343-1350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients"],"prefix":"10.1007","volume":"238","author":[{"given":"Takeshi","family":"Sakayori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amane","family":"Tateno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"5698_CR1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jphs.2015.01.007","volume":"127","author":"S Baba","year":"2015","unstructured":"Baba S, Enomoto T, Horisawa T, Hashimoto T, Ono M (2015) Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. J Pharmacol Sci 127:326\u2013331","journal-title":"J Pharmacol Sci"},{"key":"5698_CR2","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","volume":"148","author":"KL Davis","year":"1991","unstructured":"Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474\u20131486","journal-title":"Am J Psychiatry"},{"key":"5698_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/sj.jcbfm.9600411","volume":"27","author":"N Ginovart","year":"2007","unstructured":"Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, Kapur S, Wilson AA (2007) Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27:857\u2013871","journal-title":"J Cereb Blood Flow Metab"},{"key":"5698_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","volume":"66","author":"A Graff-Guerrero","year":"2009","unstructured":"Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, Rusjan P, Houle S, Wilson AA, Kapur S (2009) The effect of antipsychotics on the high-affinity state of D2 and D3 receptors; a positron emission tomography study with [11C]-(+)-PHNO. Arch Gen Psychiatry 66:606\u2013615","journal-title":"Arch Gen Psychiatry"},{"key":"5698_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1017\/S1461145709990642","volume":"13","author":"A Graff-Guerrero","year":"2010","unstructured":"Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S (2010) Blockade of [11C]-(+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 13:273\u2013287","journal-title":"Int J Neuropsychopharmacol"},{"key":"5698_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/978-3-642-25758-2_7","volume":"213","author":"G Gross","year":"2012","unstructured":"Gross G, Drescher K (2012) The role of dopamine D3 receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol 213:167\u2013210","journal-title":"Handb Exp Pharmacol"},{"key":"5698_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00210-012-0806-3","volume":"386","author":"G Gross","year":"2013","unstructured":"Gross G, Wicke K, Drescher KU (2013) Dopamine D3 receptor antagonism\u2014still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedeberg's Arch Pharmacol 386:155\u2013166","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"5698_CR8","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533\u20131539","journal-title":"J Cereb Blood Flow Metab"},{"key":"5698_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/a-0574-0088","volume":"52","author":"T Kishi","year":"2019","unstructured":"Kishi T, Matsui Y, Matsuda Y, Katsuki A, Hori H, Yanagimoto H, Sanada K, Morita K, Yoshimura R, Shoji Y, Hagi K, Iwata N (2019) Efficacy, tolerability, and safety of blonanserin in schizophrenia: an updated and extended systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry 52:52\u201362","journal-title":"Pharmacopsychiatry"},{"key":"5698_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153\u2013158","journal-title":"Neuroimage"},{"key":"5698_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pnpbp.2013.10.009","volume":"52","author":"B Le Foll","year":"2014","unstructured":"Le Foll B, Pushparaj A, Pryslawsky Y, Forget B, Vemuri K, Makriyannis A, Trigo JM (2014) Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach. Prog Neuro-Psychopharmacol Biol Psychiatry 52:86\u201393","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"5698_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/npp.2015.177","volume":"41","author":"B Le Foll","year":"2016","unstructured":"Le Foll B, Payer D, Di Ciano P, Guranda M, Nakajima S, Tong J, Mansouri E, Wilson AA, Houle S, Meyer JH, Graff-Guerrero A, Boileau I (2016) Occupancy of dopamine D3 and D2 receptors by buspirone: A [11C]-(+)-PHNO PET study in humans. Neuropsychopharmacology 41:529\u2013537","journal-title":"Neuropsychopharmacology"},{"key":"5698_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2013.07.022","volume":"719","author":"GM Leggio","year":"2013","unstructured":"Leggio GM, Salomone S, Bucolo C, Plantania C, Micale V, Caraci F, Drago F (2013) Dopamine D3 receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 719:25\u201333","journal-title":"Eur J Pharmacol"},{"key":"5698_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3389\/fnins.2016.00451","volume":"10","author":"S Maramai","year":"2016","unstructured":"Maramai S, Gemma S, Brogi S, Campiani G, Butini S, Stark H, Brindisi M (2016) Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological disease. Front Neurosci 10:451 eCollection 2016","journal-title":"Front Neurosci"},{"issue":"2","key":"5698_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1124\/jpet.114.214833","volume":"350","author":"SE Martelle","year":"2014","unstructured":"Martelle SE, Nader SH, Czoty PW, John WS, Duke AN, Garg PK, Garg S, Newman AH, Nader MA (2014) Further characterization of quinpirole-elicited yawning as a model of dopamine D3 receptor activation in male and female monkeys. J Pharmacol Exp Ther 350(2):205\u2013211","journal-title":"J Pharmacol Exp Ther"},{"key":"5698_CR16","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/npp.2010.50","volume":"35","author":"PN McCormick","year":"2010","unstructured":"McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA (2010) The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 35:1826\u20131835","journal-title":"Neuropsychopharmacology"},{"key":"5698_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.phrs.2013.01.002","volume":"70","author":"PN McCormick","year":"2013","unstructured":"McCormick PN, Wilson VS, Wilson AA, Remington GJ (2013) Acutely administered antipsychotic drugs are highly selective or dopamine D2 over D3 receptors. Pharmacol Res 70:66\u201371","journal-title":"Pharmacol Res"},{"key":"5698_CR18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1124\/jpet.107.134536","volume":"324","author":"MJ Millan","year":"2008","unstructured":"Millan MJ, Loiseau F, Dekyne A, Gobert A, Flik G, Cremers TI, Rivet JM, Sicard D, Billiras R, Brocco M (2008) S33138 (N-[4-[2-(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl] phenyl-acetamnide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 324:1212\u20131226","journal-title":"J Pharmacol Exp Ther"},{"key":"5698_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","volume":"131","author":"R Mizrahi","year":"2011","unstructured":"Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, Remington G, Wilson AA, Kapur S (2011) Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic na\u00efve patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res 131:63\u201368","journal-title":"Schizophr Res"},{"key":"5698_CR20","first-page":"213","volume":"19","author":"M Murasaki","year":"2016","unstructured":"Murasaki M (2016) The world\u2019s first dopamin serotonin antagonist? -the breakthrough of blonanserin- (Japanese). Rinsyoseishinyakuri 19:213\u2013244","journal-title":"Rinsyoseishinyakuri"},{"key":"5698_CR21","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/jcbfm.2015.129","volume":"35","author":"S Nakajima","year":"2015","unstructured":"Nakajima S, Caravaggio F, Boileau I, Chung JK, Plitman E, Gerretsen P, Wilson AA, Houle S, Mamo DC, Graff-Guerrero A (2015) Lack of age-dependent decrease in dopamine D3 receptor availability: A [11C]-(+)-PHNO and [11C]-raclopride positron emission tomography study. J Cereb Blood Flow Metab 35:1812\u20131818","journal-title":"J Cereb Blood Flow Metab"},{"key":"5698_CR22","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/sj.npp.1301163","volume":"31","author":"NM Richtand","year":"2006","unstructured":"Richtand NM (2006) Behavioral sensitization, alternative splicing, and D3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 31:2368\u20132375","journal-title":"Neuropsychopharmacology"},{"key":"5698_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1353-8020(00)00044-4","volume":"7","author":"T Sawaguchi","year":"2000","unstructured":"Sawaguchi T (2000) The role of D1-dopamine receptors in working memory-guided movements mediated by frontal cortical areas. Parkinsonism Relat Disord 7:9\u201319","journal-title":"Parkinsonism Relat Disord"},{"key":"5698_CR24","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.biopsych.2010.04.038","volume":"68","author":"G Searle","year":"2010","unstructured":"Searle G, Beaver JD, COmley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Graffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M (2010) Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and selective D3 erceptor anagonist. Biol Psychiatry 68:392\u2013399","journal-title":"Biol Psychiatry"},{"key":"5698_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/ijnp\/pyy004","volume":"21","author":"A Tateno","year":"2018","unstructured":"Tateno A, Sakayori T, Kim WC, Honjo K, NakayamaH AR, Okubo Y (2018) Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: a positron emission tomography study with [11C]-(+)-PHNO. Int J Neuropsychopharmacol 21:522\u2013527","journal-title":"Int J Neuropsychopharmacol"},{"key":"5698_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.neuroimage.2010.06.044","volume":"54","author":"AC Tziortzi","year":"2011","unstructured":"Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, Rabiner EA, Gunn RN (2011) Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dessection of D3 signal and anatomy. Neuroimage 54:264\u2013277","journal-title":"Neuroimage"},{"issue":"1","key":"5698_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41398-019-0681-5","volume":"10","author":"A Weidenauer","year":"2020","unstructured":"Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroter\u00e1n-Infante N, Pichler V, Meyer BM, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte HH, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M (2020) On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D 2\/3 receptor agonist radioligand study. Transl Psychiatry 10(1):2","journal-title":"Transl Psychiatry"},{"key":"5698_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-642-25758-2_3","volume":"213","author":"JW Young","year":"2012","unstructured":"Young JW, Amitai N, Geyer MA (2012) Behavioral animal models to assess pro-cognitive treatments for schizophrenia. Handb Exp Pharmacol 213:39\u201379","journal-title":"Handb Exp Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-020-05698-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05698-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T06:52:19Z","timestamp":1619074339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-020-05698-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5698"],"URL":"https:\/\/doi.org\/10.1007\/s00213-020-05698-3","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"After complete explanation of the study, written informed consent was obtained from all participants. This study was approved by the institutional review board of Nippon Medical School Hospital, Japan.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Y.O. has received grants or speaker\u2019s honoraria from Sumitomo Dainippon Pharma, GlaxoSmithKline, Janssen Pharmaceutical, Otsuka, Pfizer, Eli Lilly, Astellas, Yoshitomi, and Meiji within the past 3 years. The remaining authors declare no interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}